Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

Completed

• Conditions: Invasive Pneumococcal Disease
• Interventions: Drug: Pneumococcal 7-valent conjugate vaccine Prevnar

• Registration Number: NCT00227188
• Lead Sponsor: Pfizer

Brief Summary

The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2003-05
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-27
• Primary Completion: 2005-12
• Study Completion: 2005-12
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-28
• Last Update Posted: 2012-11-29

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 408

Inclusion Criteria

• All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
• Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
1	Pneumococcal 7-valent conjugate vaccine Prevnar	Children from 0-5 years of age evaluated for IPD

Trial Locations

Locations (1)

Pfizer Investigational Site; 🇪🇸 Bilbao, Spain